ArticleDiabetes care2022
Productivity Loss and Medical Costs Associated With Type 2 Diabetes Among Employees Aged 18-64 Years With Large Employer-Sponsored Insurance.
Article in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- Efficacy of the digital therapeutic glucura combined with CGM in the treatment of type 2 diabetes: a randomised controlled trial over 6 months.Diabetologia · 2026Article
- Lifestyle and Psychosocial Determinants of Type 2 Diabetes Risk Across Adulthood: The Role of Burnout in a Large Occupational Cohort.Medical sciences (Basel, Switzerland) · 2026Article
- Estimating the indirect economic burden of elevated lipoprotein(a): A 5-year simulation of cardiovascular events and associated patient and caregiver costs.American journal of preventive cardiology · 2026Article
- Work productivity, associated risk factors and costs on presenteeism and absenteeism in Chinese patients with young-onset type-2 diabetes in Hong Kong.Diabetes, obesity & metabolism · 2026Article
- Medical Costs and Productivity Losses of Atrial Fibrillation Among US Privately Insured Employees.JAMA network open · 2026Article
- Multimorbidity and the indirect cost of productivity loss from health-related work absenteeism in Belgium.European journal of public health · 2025Observational
- Health Conditions in Wyoming Miners as Reflected in Wyoming Miner's Hospital Insurance Claims, 2014-2023.Journal of occupational and environmental medicine · 2025Article
- Lifetime Health Effects and Cost-Effectiveness of Tirzepatide and Semaglutide in US Adults.JAMA health forum · 2025Article
- Clinical Outcome and Costs Based on the Degree of Vitamin K Antagonist Control for Non-Valvular Atrial Fibrillation.Journal of clinical medicine · 2025Article
- Challenges and support factors in managing type 2 diabetes among pregnant women in Thailand: A convergent mixed-methods study.Belitung nursing journal · 2025Article
- Health and Oral Health-Related Quality of Life and the Associated Factors in Diabetic Patients.Cureus · 2024Article
- Antihypertensive Medication Adherence and Medical Costs, Health Care Use, and Labor Productivity Among People With Hypertension.Journal of the American Heart Association · 2024Article
- Health and Productivity Benefits with Early Intensified Treatment in Patients with Type 2 Diabetes: Results from Korea.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveTo estimate productivity losses and costs and medical costs due to type 2 diabetes (T2D) among employees aged 18-64 years. RESEARCH DESIGN AND
methodsUsing 2018-2019 MarketScan databases, we identified employees with T2D or no diabetes among those with records on workplace absences, short-term disability (STD), and long-term disability (LTD). We estimated per capita mean annual time loss attributable to T2D and its associated costs, calculated by multiplying time loss by average hourly wage. We estimated direct medical costs of T2D in total and by service type (inpatient, outpatient, and prescription drugs). We used two-part models (productivity losses and costs and inpatient and drug costs) and generalized linear models (total and outpatient costs) for overall and subgroup analyses by age and sex. All costs were in 2019 U.S. dollars.
resultsEmployees with T2D had 4.2 excess days lost (20.8 vs. 20.3 absences, 6.4 vs. 3.3 STD days, and 1.0 vs. 0.4 LTD days) than those without diabetes. Productivity costs were 13.3% ($680) higher and medical costs were double (total $11,354 vs. $5,101; outpatient $4,558 vs. $2,687, inpatient $3,085 vs. $1,349, prescription drugs $4,182 vs. $1,189) for employees with T2D. Employees aged 18-34 years had higher STD days and outpatient costs. Women had more absences and STD days and higher outpatient costs than men.
conclusionsT2D contributes nearly $7,000 higher annual per capita costs, mostly due to excess medical costs. Our estimates may assist employers to assess potential financial gains from efforts to help workers prevent or better manage T2D.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.